Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Levofloxacin Hemihydrate

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 127Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 138199-71-0, Levofloxacin hydrate, 6gnt3y5lmf, Nofaxin, Quinsair, Volequin
    Molecular Formula
    C36H42F2N6O9
    Molecular Weight
    740.7  g/mol
    InChI Key
    SUIQUYDRLGGZOL-RCWTXCDDSA-N
    FDA UNII
    6GNT3Y5LMF
    The L-isomer of Ofloxacin.
    Levofloxacin is a Quinolone Antimicrobial.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid;hydrate
    2.1.2 InChI
    InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1
    2.1.3 InChI Key
    SUIQUYDRLGGZOL-RCWTXCDDSA-N
    2.1.4 Canonical SMILES
    CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.O
    2.1.5 Isomeric SMILES
    C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.O
    2.2 Other Identifiers
    2.2.1 UNII
    6GNT3Y5LMF
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Anhydrous, Levofloxacin

    2. Levaquin

    3. Levofloxacin

    4. Levofloxacin Anhydrous

    5. Ofloxacin, (s)-isomer

    6. Quixin

    2.3.2 Depositor-Supplied Synonyms

    1. 138199-71-0

    2. Levofloxacin Hydrate

    3. 6gnt3y5lmf

    4. Nofaxin

    5. Quinsair

    6. Volequin

    7. Levaquin (tn)

    8. Ofloxacin, (s)-

    9. Rwj-25213

    10. (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, Hemihydrate

    11. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-hydrate (2:1), (s)-

    12. Levofloxacin [usan]

    13. Dynaquin

    14. Levofloxacin (as Hemihydrate)

    15. (s)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid Hemihydrate

    16. Unii-6gnt3y5lmf

    17. Rwj 25213

    18. Tavanic Hydrate

    19. Cravit Hydrate

    20. Iquix Hydrate

    21. Quixin Hydrate

    22. Levaquin Hydrate

    23. Mfcd07772024

    24. Levofloxacin (usp)

    25. Quixin (tn)

    26. Lvfx

    27. Iquix (tn)

    28. (s)-(-)-ofloxacine

    29. (2s)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic Acid;hydrate

    30. Levofloxacin [vandf]

    31. Levofloxacin [mart.]

    32. (s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hydrate (2:1)

    33. (s)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid Hydrate(2:1)

    34. Levofloxacin Hydrate (jp17)

    35. Levofloxacin [usp-rs]

    36. Levofloxacin Hemihidrated

    37. Schembl1650602

    38. Dtxsid60160533

    39. Levofloxacin [orange Book]

    40. Levofloxacin Hydrate [jan]

    41. Levofloxacin [usp Monograph]

    42. Akos015896149

    43. Ks-1077

    44. Levofloxacin [usan:usp:inn:ban:jan]

    45. Levofloxacin Hemihydrate [who-dd]

    46. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, Hydrate (2:1), (s)-

    47. D00588

    48. Levofloxacin Hemihydrate [ep Monograph]

    49. Ofloxacin S-(-)-form Hemihydrate [mi]

    50. 199l710

    51. A886273

    52. Q47495791

    53. Levofloxacin, United States Pharmacopeia (usp) Reference Standard

    54. 3 Inverted Exclamation Mark ,5 Inverted Exclamation Mark -difluoro-4-propylbiphenyl

    55. Levofloxacin Hemihydrate, Pharmaceutical Secondary Standard; Certified Reference Material

    56. (s)-(-)-ofloxacine; Levofloxacine; (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid Hydrochloride; Levofloxacin Hemihydrate;(s)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid Hemihydrate

    57. (s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hemihydrate

    2.4 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 740.7 g/mol
    Molecular Formula C36H42F2N6O9
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count17
    Rotatable Bond Count4
    Exact Mass740.29813326 g/mol
    Monoisotopic Mass740.29813326 g/mol
    Topological Polar Surface Area148 Ų
    Heavy Atom Count53
    Formal Charge0
    Complexity634
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Drug and Medication Information
    4.1 Drug Indication

    Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

    Consideration should be given to official guidance on the appropriate use of antibacterial agents.

    Treatment of cystic fibrosis

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-Bacterial Agents

    Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

    Anti-Infective Agents, Urinary

    Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)

    Topoisomerase II Inhibitors

    Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)

    Cytochrome P-450 CYP1A2 Inhibitors

    Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    LEVOFLOXACIN
    5.2.2 FDA UNII
    6GNT3Y5LMF
    5.2.3 Pharmacological Classes
    Chemical Structure [CS] - Quinolones
    5.3 ATC Code

    J01MA12